# Can Valacyclovir Attenuate Inflammation in Antiretroviral-Treated HIV-Infected Individuals With Herpes Simplex Virus Type 2?

> **NCT01176409** · PHASE3 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 60 (actual)

## Conditions studied

- Human Immunodeficiency Virus
- Herpes Simplex

## Interventions

- **DRUG:** Valacyclovir
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01176409
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2016-05-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01176409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01176409, "Can Valacyclovir Attenuate Inflammation in Antiretroviral-Treated HIV-Infected Individuals With Herpes Simplex Virus Type 2?". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01176409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*